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Background The DANAMI-2 trial showed that in patients with ST-elevation myocardial infarction (STEMI), a strategy of inter-hos-
pital transfer for primary angioplasty was superior to on-site fibrinolysis at 30 days follow-up. This paper reports on
the pre-specified long-term composite endpoint at 3 years follow-up in DANAMI-2.
Methods
and results
We randomized 1572 patients with STEMI to primary angioplasty or intravenous alteplase; 1129 patients were
enrolled at 24 referral hospitals and 443 patients at 5 angioplasty centres. Ninety-six percent of inter-hospital trans-
fers for angioplasty were completed within 2 h. No patients were lost to follow-up. The composite endpoint (death,
clinical re-infarction, or disabling stroke) was reduced by angioplasty when compared with fibrinolysis at 3 years (19.6
vs. 25.2%, P ¼ 0.006). For patients transferred to angioplasty compared with those receiving on-site fibrinolysis, the
composite endpoint occurred in 20.1 vs. 26.7% (P ¼ 0.007), death in 13.6 vs. 16.4% (P ¼ 0.18), clinical re-infarction in
8.9 vs. 12.3% (P ¼ 0.05), and disabling stroke in 3.2 vs. 4.7% (P ¼ 0.23).
Conclusion The benefit of transfer for primary angioplasty based on the composite endpoint was sustained after 3 years. For
patients with characteristics as those in DANAMI-2, primary angioplasty should be the preferred treatment strategy
when inter-hospital transfer can be completed within 2 h.
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Introduction
Primary angioplasty for acute ST-elevation myocardial infarction
(STEMI) improves short-term clinical outcome when compared
with fibrinolytic treatment.1–8 Long-term results from randomized
trials on fibrinolysis vs. primary angioplasty are sparse and have
mainly been reported from smaller studies where all patients
were admitted directly to an angioplasty centre.2,9,10 In these
studies, the benefit of primary angioplasty was maintained during
long-term follow-up. The majority of STEMI-patients, however,
are admitted to local hospitals where primary angioplasty is not
performed.11 To offer these patients the benefit of primary angio-
plasty, they need to be transferred to invasive-treatment hospitals.
A short-term benefit of inter-hospital transfer for primary
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angioplasty has been shown previously.3,4,12,13 Long-term results
obtained by a retrospective method have only been reported
from one randomized trial (PRAGUE-2), in which inter-hospital
transfer for angioplasty was compared to on-site treatment with
streptokinase.14 The Danish multicentre randomized study of fibri-
nolytic therapy vs. primary angioplasty in acute myocardial infarc-
tion (DANAMI-2) is the largest trial that has compared on-site
fibrinolysis with inter-hospital transfer for primary angioplasty.3
We used accelerated treatment with tissue plasminogen activator
as fibrinolytic therapy. The patients in DANAMI-2 were prospec-
tively followed until 3 years after randomization for assessment
of the long-term composite endpoint, which was pre-specified in
the study protocol.15 In the present paper, we report on the clini-
cal outcome after 3 years of follow-up in DANAMI-2.
Methods
Study design
The DANAMI-2 study has been described in detail in two previous
publications.3,15 In brief, we randomly assigned patients with STEMI
to primary angioplasty or fibrinolytic therapy and followed them for
3 years. The patients were enrolled at 24 referral hospitals without
angioplasty facilities and at 5 angioplasty centres with on-site surgical
back-up. Primary angioplasty was performed on a 24 h basis, 7 days
a week. No patients were excluded from randomization or did not
undergo angioplasty due to lack of cath lab. availability. The protocol
called for randomization of 1100 patients at referral hospitals and
800 patients at angioplasty centres. Enrolment commenced in Decem-
ber 1997 and was terminated in accordance with the study protocol
on 1 October 2001 when the third interim analysis showed a signifi-
cant benefit of angioplasty in the referral hospital substudy. At that
time, 1572 patients had been randomized including 1129 patients at
referral hospitals and 443 patients at angioplasty centres.
Treatment
In both randomization groups, patients were treated with aspirin, beta-
blocker, and unfractionated heparin. Patients randomized to fibrinoly-
sis received accelerated treatment with tissue plasminogen activator
(alteplase).15 In patients randomized to primary angioplasty, stenting
of the culprit lesion was attempted in all patients, unless the vessel
had a diameter of less than 2.0 mm. Only the culprit artery was
treated at the index-angioplasty.15 Ticlopidine (500 mg) or clopidogrel
(75 mg) was given daily for 1 month after stent implantation. Platelet
glycoprotein IIb/IIIa-receptor blockers were administered at the discre-
tion of the physician. A bicycle exercise test was performed prior to
discharge in both randomization groups to assess the need for ischae-
mia driven mechanical revascularization.
Follow-up
The patients were followed as per protocol at 30 days, 1, 2, and
3 years after the index-infarct. Follow-up was performed at the hospi-
tal where the patient was randomized. None of the 1572 patients were
lost to follow-up. Six patients who emigrated were followed up by
telephone interview or during visits to Denmark. Furthermore, every
month a crosscheck was performed between the study database and
the National Person Identification Register to identify deaths among
randomized patients. When such deaths were identified, a pre-
designed questionnaire was sent to the local investigator who was
requested to obtain the relevant information about the patient’s
state of health before death and the circumstances of the death
from general practitioners, nurses, local hospitals, ambulance services,
and from autopsy data. Information about the occurrence of new myo-
cardial infarctions or strokes since the previous follow-up was also
recorded. In all cases of coronary treatment during follow-up [new
fibrinolytic treatment, new angioplasty, or coronary artery by-pass
grafting (CABG)], the hospital files were obtained. All endpoints
were continuously reviewed by an endpoint committee blinded to
randomization.15,16
Endpoints
The primary endpoint of DANAMI-2 was a composite of total mor-
tality, clinical re-infarction, and disabling stroke at 30 days of follow-up.3
In the present paper, we report on the composite endpoint after
3 years of follow-up. We also present long-term results on cardiac
death, non-cardiac death, procedure-related re-infarction, total
re-infarction rate, non-disabling stroke, and total stroke rate. Prospec-
tive long-term follow-up on these outcomes were pre-specified in
the study protocol.15 Re-infarction was classified into 18 pre-specified
categories on the basis of symptoms, ECG changes, and increases in
creatine kinase MB or troponin T above the reference limit.15 Clinical
re-infarction (nine categories) was diagnosed when re-infarction was
not related to an interventional procedure. In patients without
normalization of coronary markers, an increase of at least 50% from
the last non-normalized measurement was required. Periprocedural
re-infarction (nine categories) was diagnosed when re-infarction
occurred in relation to CABG or angioplasty during follow-up. Further-
more, we recorded long-term data on angina pectoris [according to the
Canadian Cardiovascular Society Angina Grading System (CCS class
1–4)], heart failure [according to the New York Heart Association
Classification (NYHA class 2–4)], mechanical revascularization
(angioplasty or CABG), number of re-admissions (for cardiac and non-
cardiac disease), and number of days of re-admission (for cardiac and
non-cardiac disease).
Criteria for eligibility
The criteria for inclusion were an age of 18 years or more, the pre-
sence of symptoms for at least 30 min, but less than 12 h, and cumu-
lative ST-segment elevation .4 mm in at least two contiguous leads.
The criteria for exclusion were a contraindication to fibrinolysis, left
bundle-branch block, acute myocardial infarction and fibrinolytic treat-
ment within the previous 30 days, pulseless femoral arteries, previous
coronary-bypass surgery, chronic renal failure, diabetes treated with
metformin, non-ischaemic heart disease, and non-cardiac disease
associated with a life expectancy of less than 12 months. Patients
who were judged to be at high risk during transportation because of
cardiogenic shock or severe heart failure (a sustained systolic blood
pressure 65 mmHg), persistent life-threatening arrhythmias, or a
need for mechanical ventilation were excluded from randomization.
The study complied with the Declaration of Helsinki and was approved
by the National Ethics Committee of Denmark. All patients provided
written informed consent.
Statistical design and analysis
The trial was designed as two simultaneously conducted substudies,
one involving patients randomized at referral hospitals and the other
involving patients randomized at angioplasty centres.15 Each substudy
was designed with an overall two-sided alpha of 5% and a power
(1-beta) of 80%. Results were analysed according to the
intention-to-treat principle. For the comparison of categorical vari-
ables, Pearson’s x2 test was used. Values for continuous variables
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are reported as medians and interquartile ranges (IQRs). Groups were
compared using the Mann–Whitney rank-sum test. Kaplan–Meier esti-
mates were used to describe event rates at 3 years, and Kaplan–Meier
curves were used to illustrate the cumulative event rates. The curves
were compared using the log-rank test.
Results
Baseline characteristics and medication
Baseline characteristics did not differ between patients randomized
to angioplasty vs. fibrinolysis. This was found both in the total study
population (Table 1) and in the referral hospital and angioplasty
centre substudies.3 Medication at the end of follow-up was
similar in the two treatment groups (Table 2).
Time from onset of symptoms to
treatment
Detailed results on times from onset of symptoms to admission,
randomization, transfer, and treatment have been described pre-
viously.3 In brief, median time from onset of symptoms to ran-
domization was 135 min (IQR 85–230 min) for the total study
population and there was no difference between randomization
groups (Table 1). Median time from admission to start of fibrinoly-
sis was 50 min (IQR 40–70 min). Median time from randomization
to start of fibrinolysis was 20 min (IQR 15–30 min). Median dis-
tance for transfer from referral hospitals to angioplasty centres
was 50 km with a range of 3–150 km. Median transfer time from
randomization at referral hospitals to arrival at the catheterization
laboratory was 67 min (IQR 50–85 min). Transfer time was below
2 h in 96% of transferred patients. Median total interval from onset
of symptoms to start of treatment was 224 min (IQR 171–
317 min) for patients transferred to angioplasty compared to
169 min (IQR 110–270 min) for patients randomized at referral
hospitals to receive fibrinolysis. Thus, inter-hospital transfer for
angioplasty was associated with a median treatment delay of
55 min.
Study treatment
Ninety-nine percent of patients randomized to fibrinolysis received
the assigned treatment, and 98% of patients randomized to angio-
plasty underwent immediate coronary angiography. Balloon
inflation was performed in 87% of patients randomized to angio-
plasty, and bare metal stents were implanted in 93% of patients
undergoing angioplasty.3
Composite endpoint
The superiority of primary angioplasty over fibrinolysis based on the
composite endpoint was maintained after 3 years (Table 3 and
Figure 1). For the total study population, the absolute reduction of
the composite endpoint rate was 5.7% at 30 days3 and 5.6% after
3 years. Among transferred patients, the absolute reduction of
5.7% after 30 days increased to 6.6% after 3 years. The number
needed to treat to avoid one combined endpoint within 3 years
was 18 for all hospitals and 15 for referral hospitals. In the incom-
plete substudy on patients enrolled at angioplasty centres, the absol-
ute 5.6% reduction of the composite endpoint rate after 30 days
(P ¼ 0.05) had weakened to 3.0% after 3 years (Table 3). For the
total study population, the lower rate of the composite endpoint
after angioplasty was consistent across a number of pre-specified
subgroups (Figure 2). One subgroup in which primary angioplasty
was not associated with a lower rate of the composite endpoint
was diabetics (n ¼ 113). This was due to a higher re-infarction rate
after angioplasty in diabetics as previously reported.17
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Use of medication at the end of follow-upa
Medication (%) Fibrinolysis
(n5 722)
Angioplasty
(n5 740)
P
Aspirin 92.4 92.7 0.82
Beta-blockers 68.6 70.0 0.55
ACE-inhibitors 43.8 42.4 0.61
Calcium antagonist 15.8 12.2 0.05
Nitrates 13.3 11.6 0.33
Diuretics 34.2 32.3 0.44
Lipid-lowering drug 73.4 72.8 0.81
Coumarines 5.1 5.3 0.90
Digitalis 6.2 4.9 0.25
Ticlopidine 0.0 0.7 0.03
aThe 110 patients who died during hospitalization for the index-infarct (fibrinolysis
group n ¼ 60, angioplasty group n ¼ 50) are excluded.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of the patients
Characteristic Fibrinolysis
(n 5 782)
Angioplasty
(n 5 790)
P
Age (year)
Median (IQR) 63 (54–73) 63 (54–72) 0.32
Range 28–96 23–94
Male sex (%) 73.4 73.5 0.95
Hypertension (%) 20.5 20.1 0.82
Diabetes (%) 7.1 7.4 0.80
Current smoking (%) 58.6 58.1 0.85
Previous myocardial
infarction (%)
11.8 11.0 0.61
Previous angioplasty (%) 2.6 4.3 0.05
Previous stroke (%) 4.1 2.7 0.12
Anterior index myocardial
infarction (%)
52.6 53.2 0.81
Heart rate (b.p.m.),
median (IQR)
72 (61–84) 75 (61–87) 0.44
Systolic blood pressure
(mmHg), median (IQR)
135 (115–150) 136 (120–152) 0.18
Time from onset of
symptoms to
randomization (min)
Median (IQR) 140 (85–235) 135 (85–225) 0.23
Mean (SD) 184 (+137) 184 (+151)
IQR, interquartile range.
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Secondary endpoints
After 3 years, the benefit of primary angioplasty on the
composite endpoint was achieved by lower rates of all three
secondary endpoints, but statistical significance was only reached
for clinical re-infarction (Table 3). Total mortality and the rate of
cardiac death did not differ between randomization groups
(Table 3 and Figure 3). The rate of non-cardiac death was 4.9% in
both groups (Figure 3). Among the 149 patients suffering clinical
re-infarction during 3 years follow-up, mortality was substantially
higher than in the remaining 1423 patients without clinical
re-infarction (26.3 vs. 13.1%, P, 0.001). Procedure-related
re-infarction did not differ during long-term follow-up after
primary angioplasty vs. fibrinolysis (2.7 vs. 4.1%, P ¼ 0.12,
Figure 3). When procedure-related re-infarctions and clinical
re-infarctions were combined, primary angioplasty was associated
with a significant reduction in total re-infarction rate (Figure 3).
Only one death was observed within 30 days after a
procedure-related re-infarction. There was no difference in dis-
abling stroke (Table 3) or non-disabling stroke (Figure 3) between
randomization groups. Total stroke rate was 3.7% for primary
angioplasty vs. 5.5% for fibrinolysis (Figure 3).
Mechanical revascularization, angina
pectoris, heart failure, and readmissions
during follow-up
In both randomization groups, ischaemia driven mechanical
revascularization during follow-up was mainly performed within
the first 0.5 year (Figure 4). During the last 2.5 years, there were
few coronary interventions and the event curves remained parallel
for the two groups. Mechanical revascularization during follow-up
was more frequent after fibrinolysis than primary angioplasty:
angioplasty was performed in 34% after fibrinolysis as compared
with 16% after primary angioplasty (P, 0.001) and CABG in 12
vs. 9% (P ¼ 0.07). More patients in the fibrinolysis group than in
the angioplasty group reported that they had angina pectoris at
discharge (10 vs. 5%, P, 0.001) and at 30 days follow-up (25 vs.
18%, P ¼ 0.003). In patients alive at 3 years follow-up, the differ-
ence was no longer significant (18 vs. 16%, P ¼ 0.42). Results on
heart failure did not differ significantly between randomization
groups. Fibrinolysis was associated with a higher mean number
of re-admissions for cardiac disease compared with angioplasty
(1.26 vs. 0.83 re-admissions pr. patient, P, 0.001), whereas
there was no difference on re-admissions for non-cardiac disease
(0.51 vs. 0.50, P ¼ 0.66). Correspondingly, the mean number of
days of readmissions for cardiac disease was significantly higher
in the fibrinolysis group (6.2 vs. 4.5 days pr. patient, P, 0.001),
whereas there was no difference in the mean number of days of
readmissions for non-cardiac disease (4.4 vs. 4.2, P ¼ 0.65).
Discussion
DANAMI-2 is the largest randomized trial that has compared fibri-
nolysis and primary angioplasty. The superiority of primary angio-
plasty on the composite endpoint of death, clinical re-infarction,
and disabling stroke was maintained after 3 years, both for trans-
ferred patients and for the total study population. Furthermore,
primary angioplasty significantly reduced the rates of clinical
re-infarction, coronary revascularization, and readmission for
cardiac disease. Based on our long-term findings, primary angio-
plasty should be the preferred reperfusion strategy when inter-
hospital transfer can be completed within 2 h.
Composite endpoint
In the total DANAMI-2 population and in transferred
patients, the absolute 6% reduction of the composite endpoint
achieved with primary angioplasty at 30 days was maintained
and still highly significant after 3 years. This finding is in accord-
ance with long-term results from the PRAGUE-2 trial.14 A sus-
tained benefit of primary angioplasty during long-term follow-up
was also reported from the smaller but pioneering Zwolle and
PAMI trials, in which all patients, however, were admitted directly
to angioplasty centres.9,10 Thus, the short-term superiority of
primary angioplasty over fibrinolysis was maintained during
long-term follow-up both in studies performed at angioplasty
centres and in large-scale trials where patients had inter-hospital
transfer for primary angioplasty. In DANAMI-2, the lower rate of
the composite endpoint after primary angioplasty was consistent
across a number of pre-specified subgroups. This included
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Clinical outcome at 3 years
Outcome, n (%)a Referral hospitals P Angioplasty centres P All hospitals P
Fibrinolysis
(n 5 562)
Angioplasty
(n5 567)
Fibrinolysis
(n5 220)
Angioplasty
(n5 223)
Fibrinolysis
(n5 782)
Angioplasty
(n5 790)
Death 92 (16.4) 77 (13.6) 0.18 25 (11.4) 31 (13.9) 0.41 117 (15.0) 108 (13.7) 0.46
Clinical re-infarction 63 (12.3) 46 (8.9) 0.05 26 (12.4) 14 (6.9) 0.04 89 (12.3) 60 (8.3) 0.007
Disabling stroke 24 (4.7) 17 (3.2) 0.23 6 (2.8) 5 (2.5) 0.77 30 (4.1) 22 (3.0) 0.23
Composite endpoint 150 (26.7) 114 (20.1) 0.007 47 (21.4) 41 (18.4) 0.39 197 (25.2) 155 (19.6) 0.006
Death reflects all cause mortality. Clinical re-infarction does not include procedure-related re-infarctions. Disabling stroke includes strokes with a permanent handicap of a
moderate to severe degree.15 The composite endpoint includes death, clinical re-infarction, and disabling stroke.
aPercentages are Kaplan–Meier estimates at 3 years.
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patients in whom the symptom duration was short (,2 h),
intermediate (2 to ,4 h), or relatively long (4 h). The better
long-term outcome with primary angioplasty was achieved
despite a median treatment delay of 1 h. Our findings are in
accordance with a recent meta-analysis that showed a consist-
ently better short-term outcome with primary angioplasty when
compared with fibrinolysis regardless of symptom duration and
treatment delay.1
Secondary endpoints
There was no difference in total mortality or cardiac death for
primary angioplasty when compared with fibrinolysis. Non-cardiac
mortality was the same in the two groups indicating that they had
been properly matched at randomization. Among the 1129
patients enrolled at referral hospitals, inter-hospital transfer for
primary angioplasty carried an absolute 3% lower mortality than
on-site fibrinolysis. The result did not reach significance as
DANAMI-2 was not designed as a mortality study and was termi-
nated in accordance with the study protocol when the third
interim analysis showed a significant benefit of angioplasty on the
primary composite endpoint.3,15 However, our result on mortality
was similar to findings in two meta-analyses, in which an absolute
2–3% reduction of short-term mortality after primary angioplasty
as compared with fibrinolysis was found to be highly significant.1,2
In the Zwolle trial performed at a single angioplasty centre,
long-term mortality was significantly lower in the primary angio-
plasty group after a mean follow-up of 5 years.9
The superiority of primary angioplasty over fibrinolysis based on
the composite endpoint was achieved by lower rates of all three
secondary endpoints but statistical significance was only reached
for clinical re-infarction. Re-infarction within 30 days after STEMI
has previously been associated with a significant increase in mor-
tality.18,19 We monitored clinical re-infarction during 3 years after
STEMI and found twice as many deaths in patients with clinical
re-infarction as in patients without clinical re-infarction. Thus, pre-
venting so-called non-fatal re-infarctions might carry a long-term
survival benefit. However, so far no published study has had the
statistical power and necessary long-term follow-up to support
this hypothesis. The rate of procedure-related re-infarction also
tended to be higher after fibrinolysis than primary angioplasty.
This reflected a higher rate of mechanical revascularization
during follow-up in the fibrinolysis group.
There was no difference in the rate of disabling stroke or in the
rate of non-disabling stroke for the two reperfusion modalities.
Our data on total stroke rates are in accordance with a
meta-analysis showing a lower stroke rate for primary angioplasty
when compared with fibrinolysis.2
Angina pectoris was more frequently reported in the fibrinolysis
group at discharge and at 30 days, whereas the difference when
compared with the angioplasty group was no longer significant
among patients alive after 3 years. This corresponded to a higher
rate of ischaemia driven mechanical revascularization in the fibrino-
lysis group during the first 0.5 year of follow-up. In accordance
with our results on angina pectoris and heart failure, medication
at the end of follow-up was similar in the two groups (Table 2).
Due to the higher rates of re-infarction and ischaemia driven
revascularizations, more patients assigned to fibrinolysis had
re-admissions for cardiac disease during long-term follow-up.
The number of days of re-admission for cardiac disease was also
higher after fibrinolysis. Thus, primary angioplasty was associated
with an improved long-term clinical outcome on several pre-
specified parameters in DANAMI-2.
Figure 1 The composite endpoint (total mortality, clinical
re-infarction, or disabling stroke) in the two groups
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Limitations
(i) One major limitation of this trial was that the substudy on
patients randomized at angioplasty centres only recruited
half of the stipulated patients. The premature termination of
the angioplasty centre substudy was mandated by the study
protocol when the third interim analysis in the referral hospi-
tal substudy showed a highly significant difference with
respect to the primary composite endpoint.3,15
(ii) The secondary endpoints angina pectoris and heart failure
were classified by the primary investigators who were not
blinded to the study treatment. Results on angina pectoris,
however, corresponded with the higher rates of revasculari-
zation and re-admission for cardiac disease in the fibrinolysis
group.
(iii) At the time of planning DANAMI-2, the benefit of long-term
treatment with clopidogrel both in relation to angioplasty20
and fibrinolysis21 and the benefit of using platelet glycoprotein
IIb/IIIa-receptor blockers in primary angioplasty22 and
enoxaparin in fibrinolysis23 had not been shown. Thus, an
improved long-term outcome might be achieved with both
reperfusion strategies nowadays.
(iv) Patients with failed fibrinolysis received repeated fibrinolysis
(n ¼ 26) or underwent rescue angioplasty (n ¼ 15) within
the first 12 h.3 The performance of more rescue angioplasties
might have reduced the re-infarction rate as reported by
others.24 However, clinical re-infarction only occurred in
one patient receiving repeated fibrinolysis and in one
patient undergoing rescue angioplasty in DANAMI-2.
Conclusion
Inter-hospital transfer for primary angioplasty improves the long-
term composite outcome of death, clinical re-infarction, or dis-
abling stroke when compared with on-site fibrinolysis. For patients
with clinical characteristics as those in DANAMI-2, primary angio-
plasty should be recommended when inter-hospital transfer can be
completed within 2 h.
Figure 2 The composite endpoint (total mortality, clinical re-infarction, or disabling stroke) in pre-specified subgroups
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